2022 Fiscal Year Final Research Report
Exploring Nuclear Morphological Changes and Antitumor Effects of Chemotherapy-Combined Carbon-ion Radiotherapy
Project/Area Number |
19K17260
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 52040:Radiological sciences-related
|
Research Institution | Gunma University (2021-2022) Gunma Institute of Public Health and Environmental Sciences (2019-2020) |
Principal Investigator |
|
Project Period (FY) |
2019-04-01 – 2023-03-31
|
Keywords | 重粒子線治療 / 放射線治療 / 免疫治療 / 粒子線治療 / 子宮頸がん / テーラーメード治療 / 細胞死 / 核形態 |
Outline of Final Research Achievements |
The main objective of this study was to obtain fundamental data for the establishment of concurrent chemoradiotherapy using heavy ion beams. To achieve this, we observed changes in cellular morphology when chemotherapy and radiation therapy were administered concurrently as a control study. Specifically, we compared changes in nuclear morphology in tissue samples from patients with cervical cancer before and after treatment. As a result, we found a significant increase in the expression of micronuclei when compared to the pre-treatment stage, one week after the start of treatment. Micronuclei are known to induce an immune response, and the increase in their expression provides a basic rationale for the combination therapy of radiation therapy and immunotherapy in cancer treatment in the future. This result is an important finding that has not been reported previously.
|
Free Research Field |
腫瘍放射線学
|
Academic Significance and Societal Importance of the Research Achievements |
癌治療において免疫治療が果たす役割は拡大している。今までは治療困難だった癌の制御が免疫治療の登場により可能となってきている。放射線治療領域においては重粒子線治療によって治療抵抗性だった腫瘍の制御が可能となりつつある。本研究は化学療法と重粒子線治療の併用療法の確立に向けた基礎データ取得が主目的である。その対照研究として化学療法とX線治療を併用した子宮頸がん患者の生検検体を用いた研究を行った。その結果は、同時併用前後で組織検体中の微小核の発現割合の増加が確認された。微小核は免疫応答を惹起することが知られており、化学療法と放射線治療の併用は免疫応答の起点となることが示された。
|